Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hiram Bezerra

Cardiovascular Disease Tampa, FL Medical Doctor

NPI 1528389442 CMS profile 1147167

2 Tampa General Cir, Tampa, FL 33606

Open in the dashboard

General payments

$698,442

724 records reported · program years 2019–2025

Research payments

$8,960

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$55,184

1 holding reported · through program year 2025

Research they led as principal investigator

$899,691 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Hiram Bezerra of Tampa, FL is reported in the CMS Open Payments database as having received $698,442 across 724 general payments and $8,960 in research payments paid to them. Separately, studies naming them as principal investigator received $899,691 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $55,184 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $150,242 71
2024 General $187,919 116
2023 General $111,553 87
2022 General $106,636 126
2021 General $3,637 40
2020 General $28,490 62
2019 General $109,965 222
2019 Research $8,960 2
2021 Ownership $55,184 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hiram Bezerra
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Hiram Bezerra were reported at $150,242. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Hiram Bezerra Cardiovascular Disease median Middle half National median
2019 $109,965 $450 $127–$1,392 $163
2020 $28,490 $242 $77–$751 $114
2021 $3,637 $335 $101–$1,037 $132
2022 $106,636 $395 $121–$1,211 $149
2023 $111,553 $443 $136–$1,283 $160
2024 $187,919 $450 $136–$1,323 $164
2025 $150,242 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gentuity, LLC $448,388 74 payments
  2. Abbott Laboratories $118,223 219 payments
  3. Abiomed $42,228 93 payments
  4. Medtronic Vascular, Inc. $35,393 62 payments
  5. Edwards Lifesciences Corporation $30,420 24 payments
  6. Medtronic, Inc. $13,629 166 payments
  7. HeartFlow, Inc. $4,642 5 payments
  8. Opsens Inc. $1,902 12 payments
  9. Boston Scientific Corporation $1,061 20 payments
  10. Ancora Heart, Inc. $748 1 payment
  11. Other $1,807 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $571,514 85 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $40,238 19 payments
  3. Honoraria $34,400 11 payments
  4. Food and Beverage $23,672 519 payments
  5. Travel and Lodging $22,847 86 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $5,750 3 payments
  7. Entertainment $21 1 payment
Products named General payments · program years 2019–2025
  1. Gentuity HF-OCT Imaging System $457,946 74 payments
  2. Vis-Rx $378,388 67 payments
  3. Vis-Rx Prime $60,000 6 payments
  4. Xience V coronary stent system $59,492 44 payments
  5. Impella $42,054 89 payments
  6. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $28,090 8 payments
  7. Resolute $24,978 33 payments
  8. OPTIS Vascular $20,499 24 payments
  9. OPTIS Structural Heart $16,314 9 payments
  10. COREVALVE EVOLUT R $13,073 138 payments
  11. Other $43,696 283 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $8,960 2 payments

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$67,228

Medicare's payments for the services billed

Medicare patients

174

Average age 74

Services billed

419

61 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 58%
Chronic kidney disease 52%
Diabetes 51%
Arthritis 51%
Atrial fibrillation 40%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

726 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record